Liver Cancer Pipeline Report Reveals Promising Drug Candidates and Treatment Strategies | Companies- GSK, Eureka Therapeutics, Takeda, Polaris Group, and Others

DelveInsight's, "Liver Cancer Pipeline Insight 2023" report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Liver Cancer pipeline landscape. It covers the Liver Cancer Pipeline drug profiles, including Liver Cancer clinical trials and nonclinical stage products. It also covers the Liver Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

To explore more information on the latest breakthroughs in the Liver Cancer Pipeline treatment landscape of the report, click here @ Liver Cancer Pipeline Outlook- https://www.delveinsight.com/sample-request/liver-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Liver Cancer Overview
Liver cancer is a cancer that originates in the liver, and is an aggressive tumor that frequently occurs in the setting of chronic liver disease and cirrhosis. Primary liver cancer, or hepatocellular carcinoma (HCC), is the fifth most common cancer in males and the seventh most common cancer in females, and is the third leading cause of cancer-related death worldwide.

Key Takeaways from the Liver Cancer Pipeline Report
• DelveInsight's Liver Cancer Pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Liver Cancer.
• The leading Liver Cancer Companies include Shanghai Henlius Biotech, Boehringer Ingelheim, Bristol-Myers Squibb, Jiangsu Hengrui Medicine, Glaxo SmithKline, ZAI Lab, Beijing Immunochina Medical Science and Technology, MiNA Therapeutics, Abbisko Therapeutics, Medivir AB, Teclison, Genoscience, , Eureka Therapeutics, Celsion Corporation, H3 Biomedicine, TriSalus Life Sciences, Celldex Therapeutics, Takeda, Megapro Biomedical Company, Polaris Group, and others are evaluating novel liver cancer drugs candidate to improve the treatment landscape.
• Promising Liver Cancer Pipeline therapies include Tiragolumab, VG161, IM83, MTL-CEBPA, IBR900, Talimogene Laherparepvec, SHR-1210, ABSK-011, MIV-818, TSR-022, Tirapazamine, GNS561, ET140203, Q702, Relatlimab, LioCyx-M, DKN-01, SD-101, BO-112, RO7119929, PV-10, PF-07263689, E7386, GEN2, TTI-101, MRG002, TAK-500, TAEK-VAC-HerBy, INT230-6, ARB202, QBS10072S, A166, NBTXR3, TBI-1301, CVM-1118, Namodenoson, STP705, BLU-554, SRF388, YIV-906, Tivozanib, KN046, DNAJB1-PRKACA, PTX-9908, SHR-8068, T-ACE Oil, SynOV1.1, SCT-I10A, ABX196, GT90001, ABSK-011, ADI-PEG20, HLX07, VG161, Vax NK/HCC, ERY974, Ociperlimab, HX008, CS1003, ATG-008, Icaritin, P1101, CT0181, LCAR-H93T Cells, and others.
• In May 2022, SRF388 demonstrated clinical activity in multiple solid tumor types with three confirmed partial responses across NSCLC, RCC and HCC. Confirmed partial responses (PR) were observed in two patients who received SRF388 monotherapy treatment: one in non-small-cell lung cancer (NSCLC) (previously reported) and one in clear cell renal cell carcinoma (RCC). In addition, a PR was observed in a patient who was treated with SRF388 in combination with pembrolizumab for hepatocellular carcinoma (HCC).
• In October, 2022, the U.S. Food and Drug Administration (FDA) approved a combination of the immunotherapy drugs durvalumab (Imfinzi®) plus the experimental drug tremelimumab for people with unresectable hepatocellular cancer, the most common type of liver cancer. The FDA approval was based on results of the clinical trial HIMALAYA involving 1,117 patients, led by gastrointestinal medical oncologist Ghassan Abou-Alfa at Memorial Sloan Kettering Cancer Center (MSK).
• In October 25, 2022, the US Food and Drug Administration (FDA) has granted approval for AstraZeneca's Imjudo (tremelimumab) plus Imfinzi (durvalumab) to treat adults with unresectable hepatocellular carcinoma (HCC), a kind of liver cancer.

For further information, refer to the detailed Liver Cancer Unmet Needs, Liver Cancer Market Drivers, and Liver Cancer Market Barriers, click here for Liver Cancer Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/liver-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Liver Cancer Emerging Drugs Profile

• SRF388: Surface Oncology
SRF388 is a fully human anti-IL-27 antibody designed to inhibit the activity of this immunosuppressive cytokine. Surface Oncology has identified particular tumor types, including liver, kidney and lung cancer, where IL-27 appears to play an important role in the immunosuppressive tumor microenvironment and may contribute to resistance to treatment with checkpoint inhibitors. SRF388 targets the rate-limiting p28 subunit of IL-27, and preclinical studies have shown that treatment with SRF388 blocks the immunosuppressive biologic effects of IL-27, resulting in immune cell activation in combination with other cancer therapies including anti-PD-1 therapy, as well as potent anti-tumor effects as a monotherapy.

• MTL-CEBPA: MiNA Therapeutics
MTL-CEBPA is a new medicine initially being developed as a combination therapy in cancer. MTL-CEBPA is designed to reduce immune suppression of myeloid cells by restoring C/EBP-α protein to normal levels using the RNA Activation mechanism.

• APX3330: Ocuphire Pharma
ALK-1 antibody is a potential first-in-class, fully human IgG2 neutralizing monoclonal antibody that inhibits BMP9, TGFβ through ALK-1 receptor-mediated signal transduction and tumor angiogenesis.

• Fostroxacitabine bralpamide: Medivir
Fostroxacitabine bralpamide (also named MIV-818) is a pro-drug designed to selectively treat liver cancers and to minimize side effects. It has the potential to become the first liver-targeted and orally administered drug for patients with HCC and other forms of liver cancer.

• CDX-527: Celldex Therapeutics
CDX-527 is a bispecific antibody composed of Celldex's proprietary PD-L1 and CD27 human antibodies. CDX-527 combines blockade of the PD-1 pathway with T cell costimulation through CD27 into one molecule using an IgG1-ScFv format. Preclinical data demonstrate CDX-527 is more potent than the combination of anti-PD-L1 and anti-CD27 antibodies in T cell activation and anti-tumor activity. CDX-527 has direct antibody-dependent cellular cytotoxicity (ADCC) against CD27 or PD-L1 expressing tumor cells. In addition, CDX-527 exhibits an antibody-like pharmacokinetic profile without concerning toxicity in preclinical models.

Request a sample and discover the recent advances in Liver Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Liver Cancer Treatment Landscape- https://www.delveinsight.com/sample-request/liver-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Liver Cancer Pipeline Therapeutics Assessment
There are approx. 75+ key companies which are developing the therapies Liver Cancer. The companies which have their Liver Cancer drug candidates in the most advanced stage, i.e. phase III include, Polaris Group.

Dive deep into rich insights for drugs for Liver Cancer Pipeline, click here @ Liver Cancer Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/liver-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Liver Cancer Pipeline Report
• Coverage- Global
• Liver Cancer Companies- Henlius Biotech, Boehringer Ingelheim, Bristol-Myers Squibb, Jiangsu Hengrui Medicine, Glaxo SmithKline, ZAI Lab, Beijing Immunochina Medical Science and Technology, MiNA Therapeutics, Abbisko Therapeutics, Medivir AB, Teclison, Genoscience, , Eureka Therapeutics, Celsion Corporation, H3 Biomedicine, TriSalus Life Sciences, Celldex Therapeutics, Takeda, Megapro Biomedical Company, Polaris Group, and others are evaluating novel liver cancer drugs candidate to improve the treatment landscape.
• Liver Cancer Pipeline therapies- Tiragolumab, VG161, IM83, MTL-CEBPA, IBR900, Talimogene Laherparepvec, SHR-1210, ABSK-011, MIV-818, TSR-022, Tirapazamine, GNS561, ET140203, Q702, Relatlimab, LioCyx-M, DKN-01, SD-101, BO-112, RO7119929, PV-10, PF-07263689, E7386, GEN2, TTI-101, MRG002, TAK-500, TAEK-VAC-HerBy, INT230-6, ARB202, QBS10072S, A166, NBTXR3, TBI-1301, CVM-1118, Namodenoson, STP705, BLU-554, SRF388, YIV-906, Tivozanib, KN046, DNAJB1-PRKACA, PTX-9908, SHR-8068, T-ACE Oil, SynOV1.1, SCT-I10A, ABX196, GT90001, ABSK-011, ADI-PEG20, HLX07, VG161, Vax NK/HCC, ERY974, Ociperlimab, HX008, CS1003, ATG-008, Icaritin, P1101, CT0181, LCAR-H93T Cells, and others.
• Liver Cancer Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Got Queries? Find out the related information on Liver Cancer Mergers and acquisitions, Liver Cancer Licensing Activities @ Liver Cancer Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/liver-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Liver Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Liver Cancer- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. ADI-PEG20: Polaris Group
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Brivanib alaninate: ZAI Lab
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. ABSK 011: Abbisko Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Liver Cancer Key Companies
21. Liver Cancer Key Products
22. Liver Cancer- Unmet Needs
23. Liver Cancer- Market Drivers and Barriers
24. Liver Cancer- Future Perspectives and Conclusion
25. Liver Cancer Analyst Views
26. Liver Cancer Key Companies
27. Appendix

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

This release was published on openPR.